[19] Clinical data and outcomes of unusual variants of renal cell carcinoma at a tertiary care hospital
Objective: To present our clinical data on the incidence and clinical outcomes of unusual variants of renal cell carcinoma (RCC) at a tertiary care hospital in India. RCC accounts for 2% of total cancer burden. There are several histological subtypes of RCC due to distinct molecular alterations with...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Taylor & Francis Group
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a57e453488354049bc9b36411babe9ab |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Objective: To present our clinical data on the incidence and clinical outcomes of unusual variants of renal cell carcinoma (RCC) at a tertiary care hospital in India. RCC accounts for 2% of total cancer burden. There are several histological subtypes of RCC due to distinct molecular alterations with varied clinical outcomes. Identification of these clinical variants by further immunohistochemistry markers is required for the correct diagnosis, as each clinical subtype carries its own prognostic implication. Methods: A prospective observational study over 8 years, from March 2007 to May 2016, in the M.S. Ramaiah Hospital, Bangalore, India. Results: Of 300 radical nephrectomies performed in our hospital, we found four (1.3%) cases of rhabdoid RCC, two (0.6%) of collecting duct RCC, 16 (5.3%) of chromophobe RCC, 14 (4.6%) of sarcomatoid variant of RCC (out of which eight were sarcomatoid variant of clear cell RCC, three were sarcomatoid variant of papillary RCC, and three were sarcomatoid variant of chromophobe RCC), and one (0.3%) case of medullary RCC. Conclusion: Diagnosis of different variants of RCC is very important and a high index of suspicion is required. If there is any suspicion of an unusual variant of RCC at histopathological examination, immunohistochemistry should be done for confirmation of diagnosis. Prognosis and clinical outcome is extremely poor particularly with medullary and sarcomatoid variants of RCC. A standardised therapy regime for unusual variants of RCC is not yet available due to the rarity of these unusual variants but chemotherapy can be considered in some cases of unusual variants of RCC because of the high chance of recurrence and metastasis. |
|---|